Prof. Dr. Özden Altundağ Özgeçmiş Sayfası

Prof. Dr. Özden Altundağ

Tıbbi Onkoloji Bilim Dalı
oaltundag[at]baskent.edu.tr
0(312) 246 66 66

H-İndeks 13

• Tıbbi Onkoloji (İç Hastalıkları) • İç Hastalıkları

Birleşmiş Milletler Sürdürülebilir Kalkınma Amaçları

Yayın Bilgileri


1 Large Language Models for Analyzing Cancer Drug Reimbursement Policies in Türkiye's Health Practice Regulation, Turk Onkoloji Dergisi-Turkish Journal of Oncology, 40(3), 2025 Araş.Gör.Dr. Rashad Ismayılov, Araş.Gör.Dr. Aydan Farzalıyeva, Araş.Gör.Dr. Mehmet Nezir Ramazanoğlu, Öğr.Gör. Dr. Murat Koçak, Prof. Dr. Özden Altundağ, Prof. Dr. Zafer Akçalı, Prof. Dr. Arzu Oğuz
2 Recurrence of Hepatocellular Carcinoma After Liver Transplant: A Single-Center Experience, Experimental and Clinical Transplantation, 23(8), 2025 Araş.Gör.Dr. Aydan Farzaliyeva, Araş.Gör.Dr. Mehmet Nezir Ramazanoğlu, Uzm.Dr. Adem Şafak, Prof. Dr. Arzu Oğuz, Prof. Dr. Zafer Akçali, Prof. Dr. Özden Altundağ, Prof. Dr. Mehmet Haberal
3 Automated Extraction of Key Entities from Non-English Mammography Reports Using Named Entity Recognition with Prompt Engineering, Bioengineering-Basel, 12(2), 2025 Prof. Dr. Zafer Akçali, Öğr.Gör. Hazal Selvi Çubuk, Prof. Dr. Arzu Oğuz, Öğr.Gör. Murat Koçak, Araş.Gör.Dr. Aydan Farzaliyeva, Araş.Gör.Dr. Fatih Güven, Araş.Gör.Dr. Mehmet Nezir Ramazanoğlu, Prof. Dr. Özden Altundağ, Prof. Dr. Ahmet Muhteşem Ağildere
4 Oxaliplatin-Induced Immune Thrombocytopenia in a Patient with Pancreatic Cancer, European journal of case reports in internal medicine, 11(9), 2024 Araş.Gör.Dr. Mustafa Şentürk, Prof. Dr. Özden Altundağ
5 Incidence and Clinical Characteristics of Drug-Induced Lung Disease Among Chemotherapy Recipients, Cureus Journal of Medical Science, 16(6), 2024 Prof. Dr. Özden Altundağ
6 Recent Advances in Systemic Therapy for Hepatocellular Carcinoma, Experimental and Clinical Transplantation, 22(1), 2024 Prof. Dr. Özden Altundağ
7 Brain metastasis of hepatocellular carcinoma- single center experience., INDIAN JOURNAL OF CANCER, 61(2), 2024 Prof. Dr. Arzu Oğuz, Prof. Dr. Özden Altundağ
8 Survival impact of number of removed para-aortic lymph nodes in stage I epithelial ovarian cancer, ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 305(2), 2022 Doç. Dr. Emre Günakan, Doç. Dr. Hüseyin Akilli, Araş.Gör.Dr. Atacan Timuçin Kara, Prof. Dr. Özden Altundağ, Prof. Dr. Asuman Nihan Haberal Reyhan, Prof. Dr. Mehmet Mutlu Meydanlı, Prof. Dr. Ali Ayhan
9 Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer., JOURNAL OF EVOLUTION EQUATIONS, 385(20), 2022 Prof. Dr. Özden Altundağ
10 Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer., NEW ENGLAND JOURNAL OF MEDICINE, 386(5), 2022 Prof. Dr. Özden Altundağ
11 Complications of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: An evaluation of 100 cases, INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 156(3), 2021 Prof. Dr. Ali Haberal, Doç. Dr. Hüseyin Akilli, Prof. Dr. Özden Altundağ, Prof. Dr. Ülkü Esra Kuşcu, Cagatay Taskiran, Prof. Dr. Ali Ayhan, Emre Gunakan
12 Single-Center Experience of Recurrence Patterns and Survival Analyses of Patients With Hepatocellular Carcinoma and Liver Transplant., Experimental and Clinical Transplantation, 18(2), 2020 Prof. Dr. Özden Altundağ
13 Correlation of histopathologic response and prognostic markers with the survival in locally advanced non-small cell lung cancer patients treated with neoadjuvant chemotherapy, Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, 21(1), 2019 Samed Rahatlı, Nadire Küçüköztaş, Selim Yalçın, Merih Tepeoğlu, Prof. Dr. Mehmet Dalokay Kiliç, Prof. Dr. Özden Altundağ, Doç. Dr. Merih Tepeoğlu
14 Surgical management and outcomes of metastatic tumors to the ovaries, EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 40(5), 2019 Prof. Dr. Ali Haberal, Prof. Dr. Asuman Nihan Haberal Reyhan, Prof. Dr. Ali Ayhan, Doç. Dr. Hüseyin Akilli, Prof. Dr. Özden Altundağ, Doç. Dr. Samed Rahatli
15 Fertility Sparing in Uterin Sarcomas: Single Center Experience of 13 Patients, EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 40(2), 2019 Öğr.Gör. Mehmet Tunç, Dr. Yusuf Aytaç Tohma, Dr. Hanifi Şahin, Doç. Dr. Hüseyin Akilli, Dr. Latife Atasoy Karakaş, Prof. Dr. Özden Altundağ, Prof. Dr. Ali Haberal, Dr. Ali Ayhan
16 CORRELATION OF HISTOPATHOLOGIC RESPONSE AND PROGNOSTIC MARKERS WITH THE SURVIVAL IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY , Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, 21(1), 2019 Samed Rahatlı, Nadire Küçüköztaş, Selim Yalçın, Merih Tepeoğlu, Dalokay Kılıç, Prof. Dr. Özden Altundağ
17 Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial., LANCET, 393(1018), 2019 Prof. Dr. Özden Altundağ
18 Effect of increased number of neoadjuvant chemotherapy cycles on tumor resectability and pathologic response in advanced stage epithelial ovarian cancer., Journal of BUON, 23(7), 2018 Prof. Dr. Özden Altundağ
19 The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer., ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 5(0), 2017 Prof. Dr. Özden Altundağ
20 ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up., INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 26(1), 2016 Prof. Dr. Özden Altundağ
21 ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up, ANNALS OF ONCOLOGY, 27(1), 2016 Prof. Dr. Özden Altundağ
22 ESMO-ESGO-ESTRO concensus confenece on endometrial cancer, RADIOTHERAPY AND ONCOLOGY, 7(1), 2016 Prof. Dr. Özden Altundağ
23 Treatment of Lymph Node?Negative, Early-Stage HER2-Positive Breast Cancer, JOURNAL OF CLINICAL ONCOLOGY, 34(6), 2016 Prof. Dr. Arzu Oğuz, Gül Sema Keskin, Dilşen Çolak, Prof. Dr. Özden Altundağ, Prof. Dr. Zafer Akçali
24 Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes, Journal of BUON, 21(5), 2016 Prof. Dr. Özden Altundağ
25 Trastuzumab in metastatic breast cancer after complete remission: How long is enough?, MEDICAL ONCOLOGY, 32(8), 2015 Prof. Dr. Arzu Oğuz, Doç. Dr. Samed Rahatli, Prof. Dr. Özden Altundağ, Kadri Altundağ
26 The relationship between thyroid volume and malignant thyroid disease, MEDICAL ONCOLOGY, 31(1), 2014 Prof. Dr. Özden Altundağ
27 . Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study., GYNECOLOGIC ONCOLOGY, 131(3), 2014 Prof. Dr. Özden Altundağ
28 Weekly cisplatin versus standard three-weekly cisplatin in concurrent, AMERICAN JOURNAL OF AGRICULTURAL ECONOMICS, 1(5), 2011 Prof. Dr. Özden Altundağ


1 Recurrence of hepatocellular carcinoma after liver transplantation: A single-center experience, 30th International Congress of The Transplantation-Society (TTS), 22.09.2024 Araş.Gör.Dr. Aydan Farzaliyeva, Araş.Gör.Dr. Mehmet Nezir Ramazanoğlu, Araş.Gör.Dr. Efe Hasdemir, Doç. Dr. Emre Karakaya, Prof. Dr. Arzu Oğuz, Prof. Dr. Zafer Akçali, Prof. Dr. Özden Altundağ, Prof. Dr. Mehmet Haberal
2 Posttransplant malignancies in adult transplant patients: A single center experience, 30th International Congress of The Transplantation-Society (TTS), 22.09.2024 Araş.Gör.Dr. Mehmet Nezir Ramazanoğlu, Araş.Gör.Dr. Aydan Farzaliyeva, Araş.Gör.Dr. Efe Hasdemir, Doç. Dr. Emre Karakaya, Doç. Dr. Samed Rahatlı, Prof. Dr. Arzu Oğuz, Prof. Dr. Zafer Akçali, Prof. Dr. Özden Altundağ, Prof. Dr. Mehmet Haberal
3 Automated Extraction of Key Entities from Thorax CT Reports Using NER with Prompt Engineering, 2024 World Conference on Lung Cancer, 08.09.2024 Prof. Dr. Zafer Akçali, Araş.Gör.Dr. Aydan Farzaliyeva, Araş.Gör.Dr. Fatih Güven, Araş.Gör.Dr. Mehmet Nezir Ramazanoğlu, Uzm. Dr. Efe Hasdemir, Öğr.Gör. Burak Yağdiran, Prof. Dr. Arzu Oğuz, Prof. Dr. Ahmet Muhteşem Ağildere, Prof. Dr. Özden Altundağ
4 Combined versus sequential antracycline and taxane adjuvant regimens in triple negative breast cancer patients, ASCO, 12.05.2016 Gül Sema Keskin, Prof. Dr. Arzu Oğuz, Prof. Dr. Zafer Akçali, Prof. Dr. Özden Altundağ
5 Response rates of taxane rechallenge in metastatic breast cancer patients, previously treated with adjuvant taxanes., american society of clinical oncology (ASCO), 30.05.2014 Taner Babacan, Prof. Dr. Arzu Oğuz, Prof. Dr. Özden Altundağ


Kitap Bölümü Bilgileri
1 Konjestif Kalp Yetersizliğinin İlaçla Tedavisi, In:Goodman & Gilman'ın Farmakoloji ve Tedavi El Kitabı, 477-493, 2017 Prof. Dr. Tolga Reşat Aydos, Prof. Dr. İbrahim Haldun Müderrisoğlu, Prof. Dr. Özden Altundağ, Prof Dr Özlem Turhan İyidir Prof Dr Müge Demirbilek Ekici Dr Çağdaş Şahap Oygür, Prof. Dr. Neslihan Başçil Tütüncü

Birleşmiş Milletler Sürdürülebilir Kalkınma Amaçları

Yayın Bilgileri

Kitap Bölümü Bilgileri

Ortak Yazarlar